Onego Bio

Onego Bio's Wisconsin production facility is not expected to come online until 2028, which means the tailwind it is built for — avian-flu-driven egg shortages and price spikes — may have receded by the time it can supply at scale, since egg prices are cyclical and flocks rebuild; timing a commodity-substitution business to a volatile crisis is precarious. Until that facility is running, Onego depends on contract or pilot-scale manufacturing, and the gap between "demonstrated production potential" in test vessels and reliable, cost-competitive commercial output is exactly where fermentation companies stumble. Cost is the whole ballgame: conventional egg white is a cheap commodity in normal times, so Bioalbumen must reach a price that manufacturers will pay when egg prices normalize, not just during a spike — a high bar for a precision-fermentation ingredient. The "25+ CPG collaborations" are innovation-pipeline integrations, not committed volume purchase agreements, and food-manufacturer reformulation cycles are long and easily deprioritized. At roughly $70M raised, Onego is under-capitalized against a facility targeting 6-million-hen-equivalent output — a plant of that scale costs far more than the company has raised, implying substantial additional capital (and dilution) is required, in a fermentation-funding environment that has cooled. Competition is also intensifying as other animal-free egg players (The Every Company and others) chase the same egg-volatility opening. A great product aimed at a moving target with a 2028 supply date and a funding gap is a bet on execution over a long, uncertain runway.